13 unchanged sentences
The following graph compares the cumulative total return to stockholder return on our Class A common stock relative to the cumulative total returns of the Nasdaq Composite Index, the Nasdaq Biotechnology Composite Index and the Russell 3000 Medical Equipment and Services Sector Index.
−Removed: The Nasdaq Composite Index and Nasdaq Biotechnology Composite Index have been included in the Stock Performance Graph of our Annual Reports in prior years, but we added the Russell 300 Medical Equipment and Services Sector Index to the Stock Performance Graph for the first time in this Annual Report because upon the completion of the applicable performance period, potential achievement of certain equity awards granted to certain of the Company’s executives in 2024 shall be determined in part based on the Company’s performance compared to members of such index.
−Removed: An investment of $100 is assumed to have been made in our Class A common stock and each index at market close on September 12, 2019 (the first day of trading of our Class A Common Stock on the Nasdaq Global Select Market) and its relative performance is tracked through December 31, 2024.
+Added: The Nasdaq Composite Index and Nasdaq Biotechnology Composite Index have been included in the Stock Performance Graph of our Annual Reports since our first Annual Report, which we filed in 2020, and we added the Russell 3000 Medical Equipment and Services Sector Index to the Stock Performance Graph beginning with our 2024 Annual Report.
+Added: An investment of $100 is assumed to have been made in our Class A common stock and each index at market close on December 31, 2020 and its relative performance is tracked through December 31, 2025.
Pursuant to applicable Securities and Exchange Commission rules, all values assume reinvestment of the full amount of all dividends, however no dividends have been declared on our Class A common stock to date.
−Removed: The offering price of our Class A common stock in our initial public offering (“IPO”), which had a closing stock price of $52.75 on September 12, 2019, was $39.00 per share.
The stockholder returns shown on the graph below are based on historical results and are not indicative of future performance, and we do not make or endorse any predictions as to future stockholder returns.
COMPARISON OF CUMULATIVE TOTAL RETURN
−Removed: among 10x Genomics, Inc., the Nasdaq Composite Index, the Nasdaq Biotechnology Composite Index and the Russell 3000 Medical Equipment and Services Sector Index
+Added: among 10x Genomics, Inc., the Russell 3000 Medical Equipment and Services Sector Index, the Nasdaq Composite Index, and the Nasdaq Biotechnology Composite Index
Cumulative Total Return
2 unchanged sentences
$ 100 $ 105.20 $ 25.73 $ 39.52 $ 10.14 $ 11.52
+Added: Russell 3000 Medical Equipment and Services Sector 100 120.76 93.91 98.59 104.82 110.52
Nasdaq Composite Index 100 122.18 82.43 119.22 154.48 187.14
Nasdaq Biotechnology Composite Index $ 100 $ 100.02 $ 89.90 $ 94.03 $ 93.49 $ 124.75
−Removed: Russell 3000 Medical Equipment and Services Sector Index
−Removed: $ 100 $ 124.71 $ 150.60 $ 117.11 $ 122.95 $ 130.71
Securities Authorized for Issuance under Equity Compensation Plans
1 unchanged sentence
Sales of Unregistered Securities
+Added: We completed the acquisition of Scale Biosciences, Inc.
+Added: (“Scale Bio”) on August 11, 2025, in which a portion of the consideration for the acquisition consisted of the unregistered issuance of 1,099,992 shares of our Class A common stock, valued at $13.5 million.
+Added: The sales of these securities were deemed to be exempt from registration under the Securities Act, in reliance upon Section 4(a)(2) of the Securities Act (or Regulation D or Regulation S promulgated thereunder) as transactions by an issuer not involving any public offering.
+Added: The recipients of the securities in each of these transactions represented their intentions to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends were placed upon the stock certificates issued in these transactions.
+Added: In the first quarter of 2026, we expect to pay $20.0 million, subject to any adjustments, in cash and in shares of our Class A common stock in connection with the technology transfer completed in the third quarter of 2025.
+Added: For additional information about this acquisition, see Note 4, Acquisitions, to the consolidated financial statements included in Item 8 of Part II of this Annual Report on Form 10-K.
Use of Proceeds
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.